The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.
The Trump administration may also be more aggressive targeting specific sectors, such as pharmacy benefit managers. Although ...
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...
In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...
The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback